Pfizer, the US pharmaceutical group, on Tuesday unveiled a management shake-up as part of a new structure designed to end uncertainty following its $68bn takeover of Wyeth and tap its best researchers.

In a move reflecting Pfizer’s relative weakness outside chemical-based patented drugs and a desire to maintain specialist expertise, Wyeth executives will take on senior roles in the combined company for vaccines, biological medicines and consumer health products.